Recent Regulatory 8-K events
Recent 8-Ks about regulator actions, exchange notices, compliance events, and approvals.
-
Matinas BioPharma receives NYSE American non-compliance notice; granted plan period through Oct 2027
-
Ameren Missouri files $343M electric rate increase request with MoPSC
-
Charlton Aria resolves Nasdaq filing deficiency; compliance matter closed
-
FDA accepts Replimune's BLA resubmission for RP1 in advanced melanoma; decision by Aug 2
-
BeOne Medicines settles China tax audit; pays ~RMB 446M in Q2 2026
-
eXoZymes receives $2M NIH Phase IIB SBIR grant for cannabinoid analog drug discovery
-
Heron Therapeutics receives Nasdaq notice for bid price below $1.00; 180 days to cure
-
American Express DFAST: Fed maintains minimum 2.5% SCB through Sep 2027
-
U.S. NRC begins formal review of Nano Nuclear's KRONOS MMR construction permit for UIUC deployment
-
Incannex granted US patent covering IHL-42X for obstructive sleep apnea through 2040
-
U.S. Bancorp Stress Capital Buffer unchanged at 2.6%, plans dividend increase to $0.54/share
-
SRX Global receives NYSE American delisting notice; approves 1-for-60 reverse split effective July 6
-
Consolidated Water subsidiary receives new 25-year license with lower water rates
-
JPMorgan Chase reports 2026 DFAST results; CET1 ratio minimum 12.4% under severe stress
-
FDA approves Ionis' TRYNGOLZA for severe hypertriglyceridemia, cuts pancreatitis risk 91%
-
Nasdaq Panel denies Aditxt listing; trading suspended June 25, 2026
-
Chemours agrees to $22.5M penalty and $90M in PFAS mitigation projects to settle EPA claims
-
Femasys regains compliance with Nasdaq minimum bid price rule after reverse stock split
-
NeOnc receives UAE IND approval for NEO100; Phase 2a data expected by end of July 2026
-
DevvStream receives Nasdaq delisting determination; trading suspended June 24, 2026
-
Quoin Pharma gets FDA conditional approval of brand name QYLEKI for Netherton Syndrome candidate
-
TON Strategy receives Nasdaq reprimand for excess equity awards; listing continues
-
MHRA aligns with INmune Bio on regulatory path for Ebstrocel in RDEB; UK MAA planned in 2026
-
Smith Micro regains Nasdaq minimum bid price compliance after stock closes above $1.00 for 10 days
-
Galectin reaches FDA agreement on Phase 3 endpoint for belapectin in MASH cirrhosis
-
SPS reaches $90M rate increase stipulation in NMPRC case; Xcel reaffirms EPS guidance
-
FDA grants Breakthrough Therapy Designation for Praxis Precision Medicines' elsunersen for SCN2A-DEE
-
FDA approves Spero Therapeutics' Utebzi, first oral carbapenem for cUTIs
-
Hydrofarm gets Nasdaq extension to meet equity rule; must close strategic deals
-
Claritev DOJ criminal investigation closed; civil probe ongoing
-
MPUC approves $211M rate increase for Xcel's NSP-Minnesota; ROE rises to 9.60%
-
Incyte settles CMS dispute over Opzelura Medicaid rebates; records $246M benefit
-
Silo Pharma regains compliance with Nasdaq minimum bid price rule
-
NeOnc Technologies gets UAE IND approval for NEO212 brain cancer drug
-
GRI Bio receives FDA Orphan Drug Designation for GRI-0621 in IPF
-
Algorhythm receives Nasdaq bid-price deficiency notice; 180-day cure period
-
Clover Health's Medicare Advantage contracts upgraded to 4.5 Stars for payment year 2027
-
Dyadic receives Nasdaq delisting notice for bid price and continued listing deficiencies
-
Cadrenal to file for FDA Rare Pediatric Disease Designation for tecarfarin in Kawasaki
-
IURC approves AES Indiana base rate settlement; $1.98B revenue, 9.5% ROE
-
Sleep Number receives Nasdaq delisting notice after Chapter 11 filing; trading suspended June 23
-
Corcept resubmits NDA for relacorilant to FDA for Cushing's syndrome; six-month review expected
-
Gencor regains NYSE American listing compliance after filing delayed Q1 10-Q